In vitro, a developed in-house anti-SLAMF2 mAb elicits modest antibody-dependent cell-mediated cytotoxicity and significant complement-dependent cytotoxicity against MM cell lines and primary MM plasma cells. The gene discussed is CD48; the disease is Miyoshi myopathy.